CrystalGenomics Invites Co Ltd
083790
Company Profile
Business description
CrystalGenomics Invites Co Ltd Formerly CrystalGenomics Inc is one of the leading biopharmaceutical company in Korea. The company is mainly engaged in the research and development and new drug development. It develops innovative new drug development projects such as eradication antibiotics and molecular targeted anticancer drugs. It focuses on arthritic medicines and antibiotics which kill resistant bacteria. It also offers medicines for cancer, obesity, asthma, and diabetes.
Contact
5F, A-dong, Korea Bio Park
694-1, Sampyeong-dong, Bundang-gu
Seongnam-siGyeonggi463-400
KORT: +82 316282700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
87
Stocks News & Analysis
stocks
SK Hynix Earnings: We raise fair value estimate on strong AI memory demand
Shares jumped 9% after earnings, as stronger AI memory prices boosted the chipmaker’s outlook.
stocks
Meta shares are down 12% since earnings. Is the stock a buy?
Concerns about equity sales to finance AI investments have pressured shares.
stocks
SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?
AI data center revenue is growing fast, but questions about durability remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 41.20 | 0.46% |
| CAC 40 | 7,970.00 | 83.04 | 1.05% |
| DAX 40 | 26,039.68 | 335.66 | 1.31% |
| Dow JONES (US) | 52,342.62 | 132.48 | -0.25% |
| FTSE 100 | 10,722.07 | 27.57 | 0.26% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,184.72 | 365.13 | -1.38% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,710.17 | 18.84 | 0.14% |
| S&P 500 | 7,720.22 | 23.76 | -0.31% |
| S&P/ASX 200 | 8,891.80 | 44.50 | 0.50% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |